(Q36981441)

17 August 2017

0 references

Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report (English)

1 reference

17 August 2017

Ilaria Marech

1

1 reference

17 August 2017

Angelo Vacca

2

1 reference

17 August 2017

Nicola Sivestris

3

1 reference

17 August 2017

Antonio Gnoni

4

1 reference

17 August 2017

Vito Lorusso

5

1 reference

17 August 2017

29 March 2013

1 reference

17 August 2017

1 reference

17 August 2017

5

1 reference

17 August 2017

6

1 reference

17 August 2017

1877-1880

1 reference

Epidemiology of prostate cancer and treatment remarks

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701088

Cancer treatment and survivorship statistics, 2012

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701088

Abiraterone and increased survival in metastatic prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701088

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701088

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701088

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701088

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701088

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701088

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701088

Androgen receptor antagonists (antiandrogens): structure-activity relationships

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701088

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701088

4 September 2018

Identifiers

DOI

10.3892/OL.2013.1275

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

23833660

1 reference